Display options
Share it on

Ochsner J. 2017;17(2):150-156.

Effects of Immunomodulators and Biologic Agents on Sexual Health in Patients With Inflammatory Bowel Disease.

The Ochsner journal

Ozdemir Kanar, Andrew C Berry, Rahman Nakshabendi, Ann Joo Lee, Petra Aldridge, Travis Myers, Emely Eid

Affiliations

  1. Department of Internal Medicine, University of Florida-Jacksonville, Jacksonville, FL.
  2. Department of Internal Medicine, University of South Alabama, Mobile, AL.
  3. Division of Gastroenterology, Department of Medicine, University of Florida-Jacksonville, Jacksonville, FL.
  4. Department of Biostatistics, University of Florida-Jacksonville, Jacksonville, FL.
  5. Department of Performance Data, Wheaton Franciscan Healthcare, Glendale, WI.

PMID: 28638288 PMCID: PMC5472074

Abstract

BACKGROUND: Although much knowledge has been gained regarding the medical and surgical management of inflammatory bowel disease (IBD), a paucity of information is available on the psychosexual issues related to IBD. The aim of this study was to evaluate the sexual health of patients with IBD who were taking immunomodulators and/or biologic agents vs patients with IBD who were not on that medication regimen.

METHODS: All study participants completed a validated sexual health questionnaire, the Female Sexual Function Index or the International Index of Erectile Function, to assess their subjective perception of the effect of IBD on the different domains of sexual function during the prior 1-month time period.

RESULTS: No statistically significant differences in any baseline demographic variables were found for either sex between the group taking immunomodulators/biologic agents and the nontreatment group. Among females and males, individual question responses, domain scores, and total scores showed no statistically significant differences between the 2 treatment groups.

CONCLUSION: Our data suggest that the use of immunomodulators or biologic agents does not affect female or male sexual health. However, treatment of patients with IBD must be individualized based on the aggressive nature of the disease, treatment goals, and the tolerability of various medications.

Keywords: Adjuvants–immunologic; biological factors; inflammatory bowel diseases; reproductive health

References

  1. BMC Gastroenterol. 2008 Oct 03;8:45 - PubMed
  2. J Gastroenterol. 2013 Jun;48(6):713-20 - PubMed
  3. Int J Gynaecol Obstet. 1997 Aug;58(2):229-37 - PubMed
  4. Gastroenterology. 2011 May;140(6):1785-94 - PubMed
  5. Gastroenterol Hepatol (N Y). 2014 Jan;10(1):53-5 - PubMed
  6. Surg Clin North Am. 2015 Dec;95(6):1159-82, vi - PubMed
  7. Curr Opin Gastroenterol. 2012 Jan;28(1):47-51 - PubMed
  8. Gastroenterology. 2004 May;126(6):1504-17 - PubMed
  9. Gastroenterology. 1991 Jun;100(6):1638-43 - PubMed
  10. Urology. 1997 Jun;49(6):822-30 - PubMed
  11. Gut. 1993 Apr;34(4):517-24 - PubMed
  12. Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30 - PubMed
  13. Mayo Clin Proc. 2014 Mar;89(3):355-60 - PubMed
  14. J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208 - PubMed
  15. Gastroenterol Res Pract. 2015;2015:435820 - PubMed
  16. Inflamm Bowel Dis. 2002 Nov;8(6):413-21 - PubMed

Publication Types